|
1
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sun H, Ma H, Hong G, Sun H and Wang J:
Survival improvement in patients with pancreatic cancer by decade:
A period analysis of the SEER database, 1981–2010. Sci Rep.
4:67472014. View Article : Google Scholar
|
|
4
|
Sohn TA, Yeo CJ, Cameron JL, Koniaris L,
Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH and Lillemoe
KD: Resected adenocarcinoma of the pancreas-616 patients: Results,
outcomes, and prognostic indicators. J Gastrointest Surg.
4:567–579. 2000. View Article : Google Scholar
|
|
5
|
Cho K, Ishiwata T, Uchida E, Nakazawa N,
Korc M, Naito Z and Tajiri T: Enhanced expression of keratinocyte
growth factor and its receptor correlates with venous invasion in
pancreatic cancer. Am J Pathol. 170:1964–1974. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Beenken A and Mohammadi M: The FGF family:
Biology, pathophysiology and therapy. Nat Rev Drug Discov.
8:235–253. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
August P, Javerzat S and Bikfalvi A:
Regulation of vascular development by fibroblast growth factors.
Cell Tissue Res. 8:204–210. 2003.
|
|
8
|
Powers CJ, McLeskey SW and Wellstein A:
Fibroblast growth factors, their receptors and signaling. Endocr
Relat Cancer. 7:165–197. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Turner N and Grose R: Fibroblast growth
factor signalling: From development to cancer. Nat Rev Cancer.
10:116–129. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Matsuda Y, Yoshimura H, Suzuki T, Uchida
E, Naito Z and Ishiwata T: Inhibition of fibroblast growth factor
receptor 2 attenuates proliferation and invasion of pancreatic
cancer. Cancer Sci. 105:1212–1219. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nandy D and Mukhopadhyay D: Growth factor
mediated signaling in pancreatic pathogenesis. Cancers. 3:841–871.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Corson LB, Yamanaka Y, Lai KM and Rossant
J: Spatial and temporal patterns of ERK signaling during mouse
embryogenesis. Development. 130:4527–4537. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Morita I: Distinct functions of COX-1 and
COX-2. Prostaglandins Other Lipid Mediat. 68–69:165–175. 2002.
View Article : Google Scholar
|
|
14
|
Steinbach G, Lynch PM, Phillips RK,
Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y,
Fujimura T, et al: The effect of celecoxib, a cyclooxygenase-2
inhibitor, in familial adenomatous polyposis. N Engl J Med.
342:1946–1952. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kirane A, Toombs JE, Ostapoff K, Carbon
JG, Zaknoen S, Braunfeld J, Schwarz RE, Burrows FJ and Brekken RA:
Apricoxib, a novel inhibitor of COX-2, markedly improves standard
therapy response in molecularly defined models of pancreatic
cancer. Clin Cancer Res. 18:5031–5042. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sánchez-Fidalgo S, Martín-Lacave I,
Illanes M and Motilva V: Angiogenesis, cell proliferation and
apoptosis in gastric ulcer healing. Effect of a selective cox-2
inhibitor. Eur J Pharmacol. 505:187–194. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sawaoka H, Tsuji S, Tsujii M, Gunawan ES,
Sasaki Y, Kawano S and Hori M: Cyclooxygenase inhibitors suppress
angiogenesis and reduce tumor growth in vivo. Lab Invest.
79:1469–1477. 1999.
|
|
18
|
Baguma-Nibasheka M, Barclay C, Li AW,
Geldenhuys L, Porter GA, Blay J, Casson AG and Murphy PR: Selective
cyclooxygenase-2 inhibition suppresses basic fibroblast growth
factor expression in human esophageal adenocarcinoma. Mol Carcinog.
46:971–980. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lei J, Ma J, Ma Q, Li X, Liu H, Xu Q, Duan
W, Sun Q, Xu J, Wu Z, et al: Hedgehog signaling regulates hypoxia
induced epithelial to mesenchymal transition and invasion in
pancreatic cancer cells via a ligand-independent manner. Mol
Cancer. 12:662013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jamieson NB, Mohamed M, Oien KA, Foulis
AK, Dickson EJ, Imrie CW, Carter CR, McKay CJ and McMillan DC: The
relationship between tumor inflammatory cell infiltrate and outcome
in patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol.
19:3581–3590. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mohammed A, Janakiram NB, Madka V, Brewer
M, Ritchie RL, Lightfoot S, Kumar G, Sadeghi M, Patlolla JM, Yamada
HY, et al: Targeting pancreatitis blocks tumor-initiating stem
cells and pancreatic cancer progression. Oncotarget. 6:15524–15539.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barlow M, Edelman M, Glick RD, Steinberg
BM and Soffer SZ: Celecoxib inhibits invasion and metastasis via a
cyclooxygenase 2-independent mechanism in an in vitro model of
Ewing sarcoma. J Pediatr Surg. 47:1223–1227. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
El-Rayes BF, Ali S, Sarkar FH and Philip
PA: Cyclooxygenase 2-dependent and -independent effects of
celecoxib in pancreatic cancer cell lines. Mol Cancer Ther.
3:1421–1426. 2004.PubMed/NCBI
|
|
24
|
Wei D, Wang L, He Y, Xiong HQ, Abbruzzese
JL and Xie K: Celecoxib inhibits vascular endothelial growth factor
expression in and reduces angiogenesis and metastasis of human
pancreatic cancer via suppression of Sp1 transcription factor
activity. Cancer Res. 64:2030–2038. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jimeno A, Amador ML, Kulesza P, Wang X,
Rubio-Viqueira B, Zhang X, Chan A, Wheelhouse J, Kuramochi H,
Tanaka K, et al: Assessment of celecoxib pharmacodynamics in
pancreatic cancer. Mol Cancer Ther. 5:3240–3247. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pyrko P, Soriano N, Kardosh A, Liu YT,
Uddin J, Petasis NA, Hofman FM, Chen CS, Chen TC and Schönthal AH:
Downregulation of survivin expression and concomitant induction of
apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory
analog, dimethylcelecoxib (DMC), in tumor cells in vitro and in
vivo. Mol Cancer. 5:192006. View Article : Google Scholar
|
|
27
|
Pal I and Mandal M: GSK690693 enhances
Celecoxib mediated apoptosis by an Akt mediated pathway in colon
cancer. Cancer Res. 73(Suppl 8): S10442013. View Article : Google Scholar
|
|
28
|
Molina MA, Sitja-Arnau M, Lemoine MG,
Frazier ML and Sinicrope FA: Increased cyclooxygenase-2 expression
in human pancreatic carcinomas and cell lines: Growth inhibition by
nonsteroidal anti-inflammatory drugs. Cancer Res. 59:4356–4362.
1999.PubMed/NCBI
|
|
29
|
Marek L, Ware KE, Fritzsche A, Hercule P,
Helton WR, Smith JE, McDermott LA, Coldren CD, Nemenoff RA, Merrick
DT, et al: Fibroblast growth factor (FGF) and FGF receptor-mediated
autocrine signaling in non-small-cell lung cancer cells. Mol
Pharmacol. 75:196–207. 2009. View Article : Google Scholar :
|
|
30
|
Ishiwata T, Matsuda Y, Yamamoto T, Uchida
E, Korc M and Naito Z: Enhanced expression of fibroblast growth
factor receptor 2 IIIc promotes human pancreatic cancer cell
proliferation. Am J Pathol. 180:1928–1941. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shrikhande SV, Kleeff J, Reiser C, Weitz
J, Hinz U, Esposito I, Schmidt J, Friess H and Büchler MW:
Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann
Surg Oncol. 14:118–127. 2007. View Article : Google Scholar
|
|
32
|
Friedl P and Alexander S: Cancer invasion
and the microenvironment: Plasticity and reciprocity. Cell.
147:992–1009. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shah N, Jin K, Cruz LA, Park S, Sadik H,
Cho S, Goswami CP, Nakshatri H, Gupta R, Chang HY, et al: HOXB13
mediates tamoxifen resistance and invasiveness in human breast
cancer by suppressing ERα and inducing IL-6 expression. Cancer Res.
73:5449–5458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shao W, Wang W, Xiong XG, Cao C, Yan TD,
Chen G, Chen H, Yin W, Liu J, Gu Y, et al: Prognostic impact of
MMP-2 and MMP-9 expression in pathologic stage IA non-small cell
lung cancer. J Surg Oncol. 104:841–846. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim HS, Kim MJ, Kim EJ, Yang Y, Lee MS and
Lim JS: Berberine-induced AMPK activation inhibits the metastatic
potential of melanoma cells via reduction of ERK activity and COX-2
protein expression. Biochem Pharmacol. 83:385–394. 2012. View Article : Google Scholar
|
|
38
|
Guo J, Xu Y, Ji W, Song L, Dai C and Zhan
L: Effects of exposure to benzo[a]pyrene on metastasis of breast
cancer are mediated through ROS-ERK-MMP9 axis signaling. Toxicol
Lett. 234:201–210. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhong HM, Ding QH, Chen WP and Luo RB:
Vorinostat, a HDAC inhibitor, showed anti-osteoarthritic activities
through inhibition of iNOS and MMP expression, p38 and ERK
phosphorylation and blocking NF-κB nuclear translocation. Int
Immunopharmacol. 17:329–335. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Longnecker DS and Terhune PG: What is the
true rate of K-ras mutation in carcinoma of the pancreas? Pancreas.
17:323–324. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fedorov YV, Rosenthal RS and Olwin BB:
Oncogenic Ras-induced proliferation requires autocrine fibroblast
growth factor 2 signaling in skeletal muscle cells. J Cell Biol.
152:1301–1305. 2001. View Article : Google Scholar : PubMed/NCBI
|
